22.5%
Body Weight Loss (15 mg, 72 wk)
SURMOUNT-1, peer-reviewed, FDA-approved · NEJM 2022, PMID 35658024
$36.5B
Lilly's 2025 Tirzepatide Sales
Mounjaro + Zepbound combined — now the world's best-selling drug, ahead of Keytruda
Boxed Warning
Thyroid C-Cell Tumors
Rodent data; human relevance undetermined. Contraindicated with personal/family MTC history or MEN 2
$299–$1,086
Monthly Cost, Self-Pay to List
LillyDirect self-pay vs. list price, 2026 — and the ~$150/mo compounded option was just shut down
Follow the Money
Who ProfitsTirzepatide is a genuine success story for patients AND the single most financially important product Eli Lilly has ever sold. Both things matter for reading everything that follows.
World's Best-Selling Drug
$36.5B / yr
Mounjaro (+99% YoY, $23.0B) and Zepbound (+175% YoY, $13.5B) combined to overtake Keytruda as the top-selling drug on Earth in 2025 — more than half of Lilly's entire $65.2B in revenue. That scale is real evidence of demand and real reason to read every "landmark" headline about this molecule as coming from the company with the most to gain.
Every Registrational Trial Is Lilly's
SURPASS ×5, SURMOUNT ×5
Every SURPASS (diabetes) and SURMOUNT (obesity) trial was designed, funded, run, and analyzed by Eli Lilly. The academic co-authors (Jastreboff, Rosenstock, Garvey, Frías, etc.) are paid consultants/investigators on Lilly-sponsored protocols — standard for drug development, and worth knowing while reading the numbers below.
The $150/Month Version Got Shut Down
Gone as of 3/19/2025
During the 2022–2024 supply shortage, compounding pharmacies legally sold tirzepatide for roughly $99–$150/month — a fraction of Lilly's price. The FDA declared the shortage resolved on Oct 2, 2024; 503A pharmacies lost that legal cover Feb 18, 2025, and 503B outsourcing facilities lost theirs Mar 19, 2025. Real quality problems existed at some compounders (see Regulatory section below) — but the practical effect was that the only cheap legal route to this molecule closed at the exact moment Lilly's branded supply caught up.
No Generic Competition Coming Soon
Patent to ~2036
Tirzepatide's composition-of-matter patent runs into the mid-2030s. Unlike a 60-year-old generic, there is no cheaper version waiting in the wings — the price Lilly sets is the price that exists, and every insurer/employer coverage decision is a fight over who eats that cost.
Head-to-Head: Weight Loss vs Alternatives
PubMed · Peer-ReviewedUnlike the newer investigational triple-agonists, every bar here except the last is peer-reviewed, published, and FDA-approved — not a sponsor press release. That is the real difference between tirzepatide and the drugs still in trials behind it.
Head-to-head (SURMOUNT-5, PMID 40353578): tirzepatide beat semaglutide directly in the same trial — 47.9% vs. 32.5% of participants reached ≥20% weight loss, and mean weight loss favored tirzepatide by roughly 8–10 percentage points. This is the strongest single piece of evidence that the dual mechanism outperforms the single one, in a real randomized comparison, not two separate trials being compared informally.
Mechanism: Two Receptors, Not Three
PubMed · PharmacologySemaglutide hits one gut-hormone receptor. Tirzepatide hits two. The newer investigational drugs (retatrutide) hit three — and that third receptor (glucagon) is exactly where the biggest heart-rate side effect on this whole drug class shows up. Two receptors, with several years of published trial data behind them (SURPASS-1 published 2021; approved 2022), is the "established" middle ground.
GLP-1 Receptor
Appetite ↓
Suppresses appetite via hypothalamic satiety circuits. Slows gastric emptying — the main driver of both the fullness effect and the nausea. Glucose-dependent insulin release (no hypoglycemia on its own). This is the entire mechanism semaglutide (Ozempic/Wegovy) relies on alone.
GIP Receptor
Insulin ↑, Fat ↓
Potentiates glucose-dependent insulin secretion on top of GLP-1's effect. Independently improves insulin sensitivity and modulates fat-cell signaling — the added receptor tirzepatide brings that semaglutide does not touch, and the leading mechanistic explanation for tirzepatide's larger effect size in head-to-head trials.
Peer-Reviewed & Approved
Since 2022
Unlike the investigational triple-agonists behind it in the pipeline, tirzepatide's core trials (SURPASS 1–5, SURMOUNT 1–5) have all cleared independent peer review in NEJM, Lancet, and JAMA, and the drug carries full FDA approval for both diabetes (Mounjaro) and obesity (Zepbound). Multi-year data exists. That is a real, citable difference from anything still in Phase 2/3.
Boxed Warning: Thyroid C-Cell Tumors
Class Effect
In rodents, tirzepatide causes dose- and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), at clinically relevant exposures. Whether this occurs in humans has not been determined — the same uncertainty carried by every GLP-1-class drug since liraglutide's 2010 approval, with no confirmed human MTC signal in 15+ years of use. Contraindicated in anyone with personal/family MTC history or MEN 2.
Published Human Trials — SURPASS & SURMOUNT
PubMed · Peer-Reviewed RCTsTen registrational trials, all Lilly-designed and Lilly-funded, all independently peer-reviewed and published. This is a genuinely large, mature program — the honest caveat is who ran it, not whether it was reviewed.
| # | Study | Population | n | Outcome |
|---|---|---|---|---|
| 1 |
SURPASS-1 — Monotherapy (Rosenstock et al.)
|
T2D, drug-naive | 478 | A1C ↓1.87-2.07 pts; weight ↓7.0-9.5 kg at 40 wk vs placebo |
| 2 |
SURPASS-2 — vs. Semaglutide 1mg (Frías et al.)
|
T2D, on metformin | 1,879 | Superior A1C & weight loss vs. semaglutide 1mg, all 3 tirzepatide doses |
| 3 |
SURMOUNT-1 — Obesity, No Diabetes (Jastreboff et al.)
|
Obesity/overweight | 2,539 | -20.9% (10mg) / -22.5% (15mg) body weight at 72 wk |
| 4 |
SURMOUNT-2 — Obesity + Type 2 Diabetes (Garvey et al.)
|
Obesity + T2D | 938 | -14.7% at 15mg (smaller than non-diabetic cohort — T2D blunts response) |
| 5 |
SURMOUNT-4 — Continued Treatment vs. Withdrawal
|
Obesity, responders | 670 | Stopping the drug regained 14% of body weight in 52 wk; continuing lost 5.5% more |
| 6 |
SURMOUNT-5 — Head-to-Head vs. Semaglutide
|
Obesity, no T2D | 751 | 47.9% vs 32.5% reached ≥20% loss — tirzepatide beat semaglutide directly |
Reality check: Every trial above is designed, funded, and run by Eli Lilly, and most co-authors are Lilly employees or paid consultants. That's standard pharma practice, not unique to tirzepatide — but it means there is still no independently-funded, independently-run mega-trial of this molecule. What tirzepatide has that most contested compounds on this site don't: full peer review, full FDA approval, and years of post-market surveillance data. The evidence quality is genuinely strong; the funding source is genuinely one-sided.
Muscle Loss & Body Composition — the Part the Headline Hides
PubMed · Substudy + Independent ReviewsLilly's own DEXA substudy of SURMOUNT-1 gives the real numbers directly — and independent (non-Lilly) reviewers of the whole incretin-drug class have flagged what that substudy implies at scale.
The SURMOUNT-1 Body-Composition Substudy
~25% Lean
In 160 SURMOUNT-1 participants who got DXA scans, tirzepatide produced -21.3% body weight, -33.9% fat mass, -10.9% lean mass at 72 weeks (p<0.001 vs placebo). Of all weight lost, roughly 75% was fat and 25% was lean mass — a real, measured trade-off, not a hypothetical one. Authored primarily by Lilly employees; the finding is nonetheless the company's own peer-reviewed data.
Without Resistance Training
Up to 40%
An independent (non-Lilly) analysis of the whole incretin-drug class found that without structured resistance training, lean-mass loss can run as high as 40% of total weight lost — comparable to a decade-plus of age-related muscle decline compressed into months. The reviewing group (University of Western Australia) concluded resistance exercise should be a mandatory adjunct, not an afterthought.
Sarcopenia Named Directly
"Vital Strategy"
A 2025 review by exercise-medicine researchers in Croatia and Italy, no pharma funding disclosed, states plainly that muscle loss on these drugs "may contribute to difficulties in maintaining weight over the long term and can lead to sarcopenia," and names preserving muscle mass a design priority the drug class has not solved on its own.
Independent Cross-Class Review
"Often Overlooked"
Harvard Medical School's Christos Mantzoros, MD, DSc (not a tirzepatide investigator) is senior author on a 2024 Metabolism review stating fat-free mass loss "is often overlooked" across all incretin drugs, tirzepatide included, and can "impair metabolic health and increase the risk of subsequent sarcopenic obesity" if left unaddressed.
Side Effects & Who Should Be Careful
FDA Label · Real RiskThis drug can cause real harm in specific people, and the label says so plainly — this is not a "nothing to see here" supplement page.
Common (Most People)
GI-Dominant
Nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite — dose-dependent, worst during dose escalation, the main reason people stop early. A meta-analysis of anti-obesity drugs found tirzepatide's GI side-effect burden broadly comparable to semaglutide's, both meaningfully higher than placebo.
Take Too Much / Wrong Population →
Pancreatitis & Gallbladder
Acute pancreatitis (including rare hemorrhagic/necrotizing cases) and acute gallbladder disease (cholecystitis, cholelithiasis) are documented, uncommon but real risks across the GLP-1/GIP class. A 2023 systematic review/meta-analysis found an elevated relative risk of both versus non-users, largest at higher doses. Stop and seek care for severe abdominal pain that radiates to the back, or right-upper-quadrant pain with fever.
Who Should Avoid It
Contraindicated
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — absolute contraindication per the boxed warning. Caution advised with a history of pancreatitis, severe GI disease (gastroparesis), or diabetic retinopathy (rapid glucose improvement can transiently worsen it). Not studied in pregnancy; not approved for anyone under 18 for weight loss.
Myth to Retire
Not "Ozempic Face" Inevitable
Facial/skin volume loss ("Ozempic face") is a real cosmetic effect of rapid fat loss generally, not a specific drug toxicity — it happens with any fast weight loss method, including surgery. It is not organ damage and is not in the boxed warning. Genuine risks (thyroid, pancreas, gallbladder, muscle) deserve the attention; this one is cosmetic framing dressed up as medical alarm.
Cost vs Weight-Loss Alternatives — Who Can Actually Get This
Market Data · US 2026If you're treating clinically meaningful obesity (BMI ≥30, or ≥27 with a weight-related condition) or type 2 diabetes, here's what the real options cost. Only 13 US states currently mandate insurance coverage for GLP-1-class obesity drugs, and employers are actively dropping coverage as costs climb — "FDA-approved" does not mean "affordable" for most people.
Free + Foundational
Diet + Exercise
$0
at minimum, no drug
3-5% weight loss typical
The only defense against the lean-mass loss on any of these drugs
The only defense against the lean-mass loss on any of these drugs
Semaglutide (Wegovy)
$150-1,349
/ month · compounded vs list
14.9% weight loss @ 68 wk
GLP-1 single agonist · FDA-approved, peer-reviewed
GLP-1 single agonist · FDA-approved, peer-reviewed
Most Evidence + Approved
Tirzepatide (Zepbound / Mounjaro)
$299-1,086
/ month · LillyDirect self-pay vs list
22.5% weight loss @ 72 wk
GLP-1 + GIP dual · FDA-approved, peer-reviewed
GLP-1 + GIP dual · FDA-approved, peer-reviewed
Investigational
Retatrutide (TBD brand)
Not retail
projected $1,000-1,400/mo
28.3% weight loss (claimed) @ 80 wk
Not FDA-approved; Phase 3 topline unreviewed
Not FDA-approved; Phase 3 topline unreviewed
Permanent
Bariatric Surgery
$15K-25K
one-time, often covered
25-35% weight loss at 1-2 yr
Sleeve, bypass, SADI-S
Sleeve, bypass, SADI-S
Access reality: The compounded ~$99-150/month version many patients relied on during the shortage is now restricted to documented medical necessity only (e.g., an allergy to a Lilly excipient) — cost, preference, or convenience are explicitly not valid reasons anymore. Patients who can't absorb the jump to $299-1,086/month either pay it, switch to a cheaper but less-effective option, or stop treatment — and stopping typically means regaining much of the weight (SURMOUNT-4 found 14% regain in the year after withdrawal).
FDA-Labeled Titration Schedule
PubMed · FDA LabelTirzepatide is titrated, not picked — the label schedule below is identical for Mounjaro and Zepbound and is the same escalation used across the SURPASS and SURMOUNT trials. Slow escalation exists specifically to blunt the GI side effects; there is no benefit to rushing it. The interactive calculator below the footer maps any of these doses to a syringe mark for a given vial and water mix.
Starting Dose
2.5 mg / week
Weeks 1-4 · below the effective threshold by design, purely to build tolerance
Escalation
2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg
Every 4 weeks, one step at a time — per FDA label, both products
Maintenance
5-15 mg / week
Lowest dose that achieves the desired result; not everyone needs to reach 15 mg
Critical Caveat
Lilly product ≠ compounded product
Lilly's Mounjaro/Zepbound ships as a pre-mixed liquid in single-dose pens/vials — no reconstitution needed. Compounded "tirzepatide" from a pharmacy or research-peptide vendor is typically lyophilized powder you mix yourself, which is what the calculator below models, and is now legally restricted to documented medical necessity (see Regulatory).
Regulatory & Enforcement Record
T1 · Official Agencies & Primary DocumentsFDA (USA)
Approved — Mounjaro 5/2022, Zepbound 11/2023
Full approval, not accelerated or conditional. Mounjaro covers type 2 diabetes; Zepbound covers chronic weight management (BMI ≥30, or ≥27 with a weight-related condition) plus, as of the 2025-2026 label updates, obstructive sleep apnea and cardiovascular risk reduction indications. Both carry the boxed thyroid C-cell warning.
FDA — Warning Letter to Lilly Itself
"The Video Is False or Misleading"
Sept 9, 2025: FDA sent Eli Lilly a warning letter over a direct-to-consumer video, "An Oprah Special: Shame, Blame, and the Weight Loss Revolution," that aired on ABC/Hulu featuring paid physician consultants and a Lilly VP. FDA's own words: the video "misbrands Zepbound and Mounjaro" and its distribution is "violative" under the FD&C Act. The manufacturer with the $36.5B/year franchise got disciplined for its own marketing — a useful data point on how hard the company pushes the story.
The Compounding Crackdown
50+ Warning Letters, Sept 2025
After declaring the shortage resolved (Oct 2024), the FDA sent more than 50 warning letters to GLP-1 compounders and telehealth sellers (GLP-1 Solution, Healthy Male, and others named). FDA's own letter to GLP-1 Solution states its tirzepatide products are "false or misleading" and the drugs are misbranded. Separately, a compounder (ProRx) recalled 15,000+ vials in 2024 over genuine sterility-assurance failures — both a real quality problem AND the end of the only affordable legal option existed at the same time.
WADA / Sports
Monitored, Not Yet Banned
Semaglutide has been tracked under WADA's Monitoring Program since 2024; tirzepatide markers were added Jan 1, 2026. Monitoring means WADA collects data to detect patterns of use — it is not a prohibition, and no Therapeutic Use Exemption is currently required. A decision on full Prohibited-List status is possible before the 2028 LA Olympics but has not been made.
The Investigators & the Practitioners Who Actually Prescribe It
Academic Trials + Real-World Clinic Data
Two different groups shown here on purpose. The trial investigators designed and ran Lilly's own studies — credentialed, real, and also paid consultants on the sponsor's protocols. The real-world clinicians below are independent of Lilly's trial program: they prescribe the drug in their own clinics and publish what actually happens to their own patients.
Dr. Ania M. Jastreboff, MD, PhD
PI · SURMOUNT-1
First author on SURMOUNT-1 (NEJM 2022), the pivotal obesity trial. Director, Yale Obesity Research Center; Professor of Medicine (Endocrinology) and Pediatrics, Yale School of Medicine. Yale's investigator-disclosure standards require her to report Lilly consulting/research ties — standard for the field, and worth knowing when reading her public statements on the drug class.
Dr. Julio Rosenstock, MD
PI · SURPASS-1 & -2
Lead/senior author on both SURPASS-1 (monotherapy) and SURPASS-2 (vs. semaglutide) — the first two registrational trials in humans. Director, Dallas Diabetes Research Center at Medical City; one of the most-cited diabetes trialists of the last 20 years, and a paid Lilly consultant/investigator across multiple GLP-1-class programs.
Dr. Gitanjali Srivastava, MD, FACP, FAAP
2,306 Real Patients
Director of Clinical Obesity Medicine and co-director of the Vanderbilt Weight Loss Center. Not a Lilly trial investigator — senior author on a 2025 real-world cohort of 2,306 patients at her own academic obesity clinic (117 on tirzepatide alone, 575 on both agents). Median treatment persistence: 10.7 months, in patients managed with real insurance friction and real dropout, not trial-protocol monitoring. Board-certified in obesity medicine (ABOM) and internal medicine.
Dr. Christopher McGowan, MD, ABOM, AGAF, FASGE
Triple Board-Certified
Founder and Medical Director of True You Weight Loss (Cary, NC), the first practice of its kind in the US. Triple board-certified in internal medicine, gastroenterology, and obesity medicine (ABOM 2019). Independent of Lilly's trial program; prescribes and manages tirzepatide/semaglutide directly and also performs endoscopic (non-drug) weight-loss procedures — a genuine competing revenue stream, disclosed here so the reader can weigh it.
PubMed vs. the Doctors + Real-World Voices
T-Doc + Anecdotal · Real-World Voices
Verified against yt-dlp metadata pulled live this session — title, uploader, upload date, view count and duration below were resolved directly, not assumed. Financial interest disclosed for every speaker: all of the doctors below run practices that prescribe and profit from GLP-1-class therapy, exactly like the trial investigators above profit from Lilly's research funding. That symmetry matters more than any single opinion.
Dr. Ashley Froese, DO
"GLP-1 Revolution" · 4,801 views
Board-certified family-medicine physician, Direct Primary Care clinic (Mesa, AZ). Her video "The GLP-1 Revolution: Weight Loss Drugs That ACTUALLY Work" (uploaded 2025-08-19, 6:29 runtime, 4,801 views as pulled live) covers tirzepatide/semaglutide mechanism, dosing logic, and safety. Consistent theme across her channel: these are chronic treatments, not quick fixes, and muscle preservation needs a deliberate plan, not an afterthought. Financial interest: her clinic prescribes these drugs directly.
Dr. Christopher McGowan, MD
Zepbound vs. Wegovy · 203,956 views
His video "How does Zepbound (tirzepatide) compare to Wegovy (semaglutide)?" (uploaded 2023-11-10, 5:04 runtime, 203,956 views as pulled live) walks through the dual-mechanism argument for patients directly, from a clinician who prescribes both. Financial interest: his clinic sells GLP-1 management and competing endoscopic procedures.
Compounded-Era Patients
~$100-150/mo → Gone
Real reports from the 2023-2025 compounding window describe genuine weight-loss success at a fraction of the branded price, alongside real reports of inconsistent dosing and product-quality concerns at some pharmacies. Both threads are true. Independent reporting (Stanford Medicine, CNN) documents patients losing access entirely once the shortage designation was lifted and enforcement discretion ended.
CNN — Independent Reporting
"Threatening Supply and Access"
CNN's May 2025 coverage of the crackdown framed it plainly: enforcement against off-brand tirzepatide/semaglutide was "threatening supply and access for many," even as FDA cited legitimate quality-control failures at some compounders as the stated justification. Both the safety concern and the access harm are reported here at equal weight, not resolved for you.
New to Tirzepatide? Start Here.
Tirzepatide is a once-weekly injectable that hits two gut-hormone receptors at once (GLP-1 and GIP). Sold as Mounjaro for type 2 diabetes and Zepbound for obesity — same molecule, different FDA approval, different box. It's real, published, peer-reviewed, and it made Eli Lilly $36.5 billion in 2025, more than any other drug on Earth. It also comes with a boxed thyroid-tumor warning, real muscle loss you have to actively fight, and a price that just got a lot harder to avoid paying in full. Here's the whole picture, not the ad version.
What it is
A once-weekly injectable dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. FDA-approved — Mounjaro for type 2 diabetes (May 2022), Zepbound for chronic weight management (November 2023). Not investigational; not gray-market by default (though gray-market compounded versions exist, see Regulatory).
What it does — and costs
Suppresses appetite, slows gastric emptying, boosts glucose-dependent insulin release, improves insulin sensitivity. Real Phase 3 result: up to 22.5% body-weight loss at 72 weeks, peer-reviewed and published. Costs $299-1,086/month depending on dose and payment path; insurance coverage is patchy.
How it's given
One subcutaneous injection per week. Dose escalation over roughly 5 months: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, one step every 4 weeks. Treatment is chronic, not a finite cycle — stopping typically means regaining a meaningful share of the weight within a year.
Can I get it?
Yes, with a prescription — it's FDA-approved and legally available at pharmacies or via LillyDirect. What you can no longer legally get is the cheap compounded version for cost/convenience reasons; compounding is now restricted to documented medical necessity (e.g., an excipient allergy) after the FDA declared the national shortage resolved.
What to weigh, not a verdict
The trial numbers are real, peer-reviewed, and approved — genuinely stronger evidence than most compounds on this site. So are the open costs: a real boxed warning, documented muscle loss you have to actively counter with resistance training, an FDA warning letter against Lilly's own marketing, and a price that just became harder to avoid paying in full. Whether that trade is worth it is a decision for you and a doctor who isn't the one selling you the drug.
Common Questions, Honest Answers
Grounded in the published data where it exists, flagged clearly where it's sponsor-only or still unsettled.
How is this different from Ozempic / Wegovy (semaglutide)?
Same drug class, one extra receptor. Semaglutide hits GLP-1 alone; tirzepatide adds GIP. In a direct head-to-head trial (SURMOUNT-5), tirzepatide beat semaglutide — 47.9% of patients reached ≥20% weight loss vs. 32.5% on semaglutide. Both are once-weekly injections, both FDA-approved and peer-reviewed.
And vs. retatrutide (the newer triple-agonist)?
Retatrutide adds a third receptor (glucagon) and claims a larger weight-loss number (28.3%) — but that number is Lilly's own unreviewed press release, not published peer-reviewed data, and retatrutide is not FDA-approved. Tirzepatide's 22.5% is a real, published, approved number. "Bigger claimed number, unapproved" vs. "smaller proven number, approved and available now" is the actual trade.
What are the real side effects?
Mostly GI: nausea, vomiting, diarrhea, constipation — worst during dose escalation. The boxed warning is thyroid C-cell tumors (rodent data; human relevance unknown). Documented but less common: acute pancreatitis, gallbladder disease. Real and measured: roughly a quarter of all weight lost is lean/muscle mass without a deliberate resistance-training plan.
Will the weight stay off if I stop?
Probably not, at least not all of it. SURMOUNT-4's own withdrawal arm found patients who stopped tirzepatide regained about 14% of their lost weight within a year, while those who continued lost another 5.5%. Obesity is being treated here as a chronic condition — like blood pressure medication, stopping usually means the underlying problem returns.
Can I still get the cheap compounded version?
Generally, no. The FDA declared the tirzepatide shortage resolved in October 2024. 503A compounding pharmacies lost their legal cover in February 2025 and 503B outsourcing facilities in March 2025. Compounding is now restricted to documented medical necessity (e.g., a genuine allergy to a Lilly excipient) — cost or convenience no longer qualify, and the FDA has sent 50+ warning letters to sellers who kept marketing it anyway.
Is it safe to buy "tirzepatide" online?
Buying from an unlicensed online seller today is legally and practically risky: FDA warning letters in September 2025 named specific sellers whose tirzepatide products it called "false or misleading," and one licensed compounder (ProRx) recalled 15,000+ vials in 2024 over sterility-assurance failures. A licensed pharmacy dispensing an FDA-approved Lilly product, or a compounder with a documented medical-necessity exception, are the verifiable paths; a random research-peptide website is not.
Does it work for type 2 diabetes too?
Yes — it was approved for diabetes (Mounjaro) 18 months before obesity (Zepbound). SURPASS-2 showed it beat semaglutide 1mg on both A1C and weight in people with type 2 diabetes on metformin. SURMOUNT-2 (obesity + diabetes together) showed a smaller weight-loss effect (-14.7% vs up to -22.5% in non-diabetics) — diabetes itself blunts the weight response somewhat.
Smartest way to think about the cost?
Check insurance coverage first — only 13 states mandate it for obesity, but diabetes coverage (Mounjaro) is broader. If self-pay, LillyDirect's $299-449/month vial program is meaningfully cheaper than the $1,086/month list price, but requires refilling within a 45-day window to keep that rate. Budget for years, not months — SURMOUNT-4 shows stopping largely reverses the benefit.
Key Takeaways
- 22.5% weight loss (15mg, 72 wk) in a peer-reviewed, FDA-approved trial — and it beat semaglutide directly in a randomized head-to-head (SURMOUNT-5)
- Made Eli Lilly $36.5 billion in 2025 — the best-selling drug on Earth — and every registrational trial was Lilly-designed and Lilly-funded
- Boxed warning for thyroid C-cell tumors (rodent data; contraindicated with personal/family MTC history or MEN 2); real, documented risk of pancreatitis and gallbladder disease
- Roughly a quarter of all weight lost is lean/muscle mass in Lilly's own DEXA substudy — resistance training is not optional if you want to keep it
- The FDA sent Lilly itself a warning letter over misleading DTC marketing, and 50+ warning letters to compounders selling the cheaper version
- The ~$100-150/month compounded option is now legally restricted to documented medical necessity — branded self-pay runs $299-1,086/month, and stopping typically means regaining much of the weight
- Genuinely stronger evidence than most compounds on this site — peer-reviewed, approved, years of data — and genuinely one-sided funding. Both are true at once.